Browsing Conditions, Lifestyle Factors & Interventions by Subject "Antipsychotics"
Now showing items 1-20 of 24
-
Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study
(2020-07)Background Evidence for the effectiveness of treatments in early-onset psychosis is sparse. Current guidance for the treatment of early-onset psychosis is mostly extrapolated from trials in adult populations. The UK ... -
Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS)
(2020-07)Background Clinicians’ treatment beliefs could affect the feasibility of delivering different treatments in a randomised controlled trial (RCT). In MAPS (Managing Adolescent first Episode Psychosis: a feasibility Study), ... -
Clozapine and Sweet's syndrome: case report
(2023-09)A patient developed fever, raised inflammatory markers and a maculopapular rash following commencement of clozapine for treatment of his schizoaffective disorder. Skin biopsy confirmed Sweet's syndrome. Identification of ... -
Clozapine-induced pericarditis: an ethical dilemma
(2019-06)Clozapine is an atypical antipsychotic used most frequently in the management of treatment-resistant schizophrenia, where severely unwell patients have failed to respond to standard antipsychotic therapy. Clozapine is ... -
Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment
(2019-12)Bipolar disorder is an illness characterised by periods of elated and depressed mood. These mood episodes are associated with changes in cognitive function and there is evidence to suggest that cognitive dysfunction persists ... -
Comparative effects of 18 antipsychotics on metabolic function in schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
(2019-10)Background: Antipsychotic-treatment is associated with metabolic disturbance. However, the relative degree to which metabolic alterations occur in treatment with different antipsychotics remains unclear. Furthermore, ... -
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis
(2022-02)Schizophrenia is a common, severe, and usually chronic disorder. Maintenance treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We aimed to compare the efficacy and tolerability of ... -
Efficacy and Effectiveness of Antipsychotics in Schizophrenia: Combining Evidence from Randomised Controlled Trials and Real-World.
(2023-10)Background: There is debate about the generalisability of results from randomised clinical trials (RCTs) to ‘real-world’ (RW) settings. Studying outcomes of treatments for schizophrenia can shed light on this issue and ... -
How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices
(2021-08)Background The magnitude of the superiority of antipsychotics over placebo is debated. One reason is that the effect-size index which is usually used in meta-analyses is in standard deviation units. Many other indices, ... -
Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study
(2019-04-15)In medicine, algorithms can inform treatment decisions by combining the most up-to-date evidence about side effect profiles of medications, which are comparable in efficacy. Their use provides opportunities for improved ... -
Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders?
(2022-08)Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety ... -
A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry
(2018-07)There are 12 billion injections given worldwide every year. For many injections, the intramuscular route is favoured over the subcutaneous route due to the increased vascularity of muscle tissue and the corresponding ... -
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
(2023-06)Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate ... -
Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study
(2022-06)Introduction Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated ... -
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis
(2022-06)Background: Brexpiprazole augmentation is an effective treatment strategy for antidepressant-refractory depression, but its optimal dosage remains unclear. Aims: To find the optimal dosage of brexpiprazole as augmentation ... -
Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT
(2021-01)Background: When psychosis emerges in young people there is a risk of poorer outcomes, and access to evidence-based treatments is paramount. The current evidence base is limited. Antipsychotic medications show only a small ... -
The relationship between striatal dopamine and anterior cingulate glutamate in first episode psychosis changes with antipsychotic treatment
(2023-05)The neuromodulator dopamine and excitatory neurotransmitter glutamate have both been implicated in the pathogenesis of psychosis, and dopamine antagonists remain the predominant treatment for psychotic disorders. To date ... -
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
(2022-02)IMPORTANCE Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent ... -
Rischio di mortalità con i farmaci antipsicotici nella popolazione psichiatrica anziana? Una revisione sistematica della letteratura
(2016)Scopo dello studio: In Italia, gli anziani raggiungono quasi un quarto della popolazione generale. In questo sottogruppo, gli antipsicotici sono ampiamente prescritti: nonostante siano autorizzati esclusivamente per ... -
Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/ hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects
(2020-06)Mental disorders frequently begin in childhood or adolescence. Psychotropic medications have various indications for the treatment of mental disorders in this age group and are used not infrequently off‐label. However, ...
